BiotechPark with Innovation- and Incubationscenter

diagram

Berlin-Buch, with its long tradition of excellent biomedical basic and clinical research as well as clinical expertise, is an ideal environment for life science companies. The campus atmosphere is conducive to scientific exchange, technology transfer and collaborative projects.

With an area of approximately 45,000 m², the BiotechPark Berlin-Buch is one of the largest biotech parks in Germany. Here entrepreneurs and companies find affordable, industry-specific laboratory and office space with state-of-the-art facilities. Start-ups can grow and thrive in the Innovation and Incubation Center, building areas on the Campus allow for future development. The managing company, Campus Berlin-Buch GmbH, supports the companies in all matters and provides comprehensive service.
Currently, 75 companies are located on campus and employ around 850 people. More than fifty of these companies are in the biotech sector, several others offer services for the life science industry. Since 1998 the number of employees of the biotech companies has more than doubled.

The business fields of the companies range from medical technology products, molecular biological diagnostics and treatments, preclinical pharmacological and pharmacogenomic tests, RNA technologies, the search for pharma-relevant target molecules, production and testing of drugs and the analysis and synthesis of biomolecules.

From 2023 the new BerlinBioCube start-up center in BiotechPark Berlin-Buch will offer an additional 8,000 square meters of laboratory and office space and attractive services for start-ups in the fields of biotechnology and medical technology as well as adjacent areas.

„Made in Buch“ stands for high quality and innovation in the life sciences. Selected products can be found here.

Otto Warburg House

News innovation

Pentixapharm Acquires Target Discovery Business of Glycotope

Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective...

more ...

Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler

Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a broad range of malignancies, announced today that the General Shareholder Mee...

more ...

Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG

The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 20...

more ...

Events Campus

10.09.2024, 09:00
From Target to Market - The GLA Biotech & Pharma Summer School

The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea to the market.

more ...

12.09.2024, 09:00
Realtime PCR und digital PCR Kurs

Der RealTime PCR und Digital PCR Kurs richtet sich an erfahrene PCR Anwender*innen und an Einsteiger*innen. Wichtige PCR Grundlagen werden erörtert, bevor die RealTime PCR besprochen und Genexpression...

more ...

08.10.2024, 09:00
GMP Biotech Summer School

Good Manufacturing Practice (GMP) Basic Course Biotechnology (English) & ATMPs

more ...

Sponsoren der Website: